Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA4 | P43681 | 20/20 | 0.64 |
| ▸ | CHRNB2 | P17787 | 19/20 | 0.64 |
| ▸ | CHRNB4 | P30926 | 19/20 | 0.64 |
| ▸ | CHRNA3 | P32297 | 19/20 | 0.64 |
| ▸ | CHRNA7 | P36544 | 17/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL745134 | 0.98 | CHRNA4 (0.61) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL30359105 | 0.81 | CHRNA4 (0.43) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL1464770 | 0.81 | CHRNA4 (0.63) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL25372135 | 0.80 | CHRNB2 (0.64) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL2186724 | 0.80 | CHRNB2 (0.64) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL5773702 | 0.80 | CHRNB2 (0.64) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL25391666 | 0.80 | CHRNB2 (0.64) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL4636609 | 0.79 | — | — | |
| SCHEMBL24693316 | 0.78 | CHRNA4 (1.00) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL24014154 | 0.78 | CHRNB2 (0.61) | CHRNA4CHRNB2CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119053606-A | Bicyclic carboxamide derivatives | 住友制药株式会社 | 2024-11-29 | — | — | CN | claimed |
| CN-114901640-A | Novel compounds useful for the treatment of dyslipidemia | 兹杜斯生命科学有限公司 | 2022-08-12 | — | — | CN | claimed |
| US-12448382-B2 | Heterocyclic compounds for mediating tyrosine kinase 2 activity | GUANGZHOU INNOCARE PHARMA TECH CO. LTD. (CN) | 2025-10-21 | — | — | US | disclosed |
| CN-119053606-A | Bicyclic carboxamide derivatives | 住友制药株式会社 | 2024-11-29 | — | — | CN | disclosed |
| CN-118785904-A | Conjugates of TASK1/3 channel blockers and P2X3 receptor antagonists for the treatment of sleep apnea | 拜耳公司 | 2024-10-15 | — | — | CN | disclosed |
| CN-118541153-A | Conjugates of a TASK1/3 channel blocker and a norepinephrine reuptake inhibitor for the treatment of sleep apnea | 拜耳公司 | 2024-08-23 | — | — | CN | disclosed |
| CN-118434415-A | Conjugates of TASK1/3 channel blockers and muscarinic receptor antagonists for the treatment of sleep apnea | 拜耳公司 | 2024-08-02 | — | — | CN | disclosed |
| CN-114096532-B | Heterocyclic compounds which inhibit tyrosine kinase 2 activity | 广州诺诚健华医药科技有限公司 | 2023-12-01 | — | — | CN | disclosed |
| CN-110678177-B | Pyrazole MAGL inhibitors | H.隆德贝克有限公司 | 2023-06-13 | — | — | CN | disclosed |
| WO-2023064370-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND USE THEREOF | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2023-04-20 | — | — | WO | disclosed |
| CN-114901640-A | Novel compounds useful for the treatment of dyslipidemia | 兹杜斯生命科学有限公司 | 2022-08-12 | — | — | CN | disclosed |
| WO-2010132599-A1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | WO | disclosed |
| US-20100292208-A1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | disclosed |
| US-20100292208-A1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-11-18 | — | — | US | disclosed |
| EP-2217237-A1 | ARYL-SUBSTITUTED BRIDGED OR FUSED DIAMINES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | Janssen Pharmaceutica N.V. (BE) | 2010-08-18 | — | — | EP | disclosed |
| WO-2009126806-A2 | THIAZOLOPYRIDIN-2-YLOXY-PHENYL AND THIAZOLOPYRAZIN-2-YLOXY-PHENYL AMINES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-15 | — | — | WO | disclosed |
| US-20090258854-A1 | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-15 | — | — | US | disclosed |
| US-20090258854-A1 | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2009-10-15 | — | — | US | disclosed |
| WO-2009058347-A1 | ARYL-SUBSTITUTED BRIDGED OR FUSED DIAMINES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-05-07 | — | — | WO | disclosed |
| US-20090111794-A1 | Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111794-A1 | Aryl-substituted bridged or fused diamines as modulators of leukotriene A4 hydrolase | LTA4H, LTB4R, LTC4S | CHRNA4 1758/4885CHRNB2 3755/4885CHRNB4 1645/4885 |
| US-20100292208-A1 | COMPOUNDS WITH TWO FUSED BICYCLIC HETEROARYL MOIETIES AS MODULATORS OF LEUKOTRIENE A4 HYDROLASE | LTA4H, LTC4S, LTB4R | CHRNA4 924/4885CHRNB2 2508/4885CHRNB4 795/4885 |
| US-20090258854-A1 | Thiazolopyridin-2-yloxy-phenyl and thiazolopyrazin-2-yloxy-phenyl amines as modulators of leukotriene A4 hydrolase | LTA4H, LTC4S, LTB4R2 | CHRNA4 1072/4885CHRNB2 2274/4885CHRNB4 1134/4885 |
| US-12448382-B2 | Heterocyclic compounds for mediating tyrosine kinase 2 activity | TYK2, JAK2, JAK1 | CHRNA4 4862/4885CHRNB2 4573/4885CHRNB4 4848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.